Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSUREā„¢ registry.

Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR.

J Urol. 2014 Apr;191(4):964-70. doi: 10.1016/j.juro.2013.10.098. Epub 2013 Oct 29.

2.

Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry.

Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W.

Cancer. 2011 Oct 1;117(19):4406-13. doi: 10.1002/cncr.26064. Epub 2011 Mar 15.

3.

Re: Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSUREā„¢ registry: K. C. Cary, N. Singla, J. E. Cowan, P. R. Carroll and M. R. Cooperberg. J Urol 2014; 191: 964-970.

Goonewardene SS, Persad R, Young A, Makar A.

J Urol. 2014 Dec;192(6):1889-90; discussion 1890-1. doi: 10.1016/j.juro.2014.06.091. Epub 2014 Sep 4. No abstract available.

PMID:
25194545
4.

Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.

Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR.

Eur Urol. 2015 Oct;68(4):600-8. doi: 10.1016/j.eururo.2014.08.074. Epub 2014 Sep 18.

5.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators..

Cancer. 2006 Apr 15;106(8):1708-14.

6.

The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.

Lubeck DP, Grossfeld GD, Carroll PR.

Urology. 2001 Aug;58(2 Suppl 1):94-100. Review.

PMID:
11502459
7.
9.

Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.

Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR.

Eur Urol. 2015 Sep;68(3):480-6. doi: 10.1016/j.eururo.2015.01.008. Epub 2015 Feb 2.

10.

Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.

Park S, Meng MV, Elkin EP, Speight JL, DuChane J, Carroll PR.

J Urol. 2005 Nov;174(5):1802-7.

PMID:
16217291
11.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
12.
13.

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.

Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P.

Lancet Oncol. 2012 Dec;13(12):1260-70. doi: 10.1016/S1470-2045(12)70423-0. Epub 2012 Nov 12. Erratum in: Lancet Oncol. 2014 Sep;15(10):e417. Dosage error in article text.

PMID:
23151431
14.
15.

Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer.

Timilshina N, Breunis H, Alibhai SM.

J Urol. 2012 Dec;188(6):2183-8. doi: 10.1016/j.juro.2012.08.018. Epub 2012 Oct 18.

PMID:
23083859
16.

Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.

Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV.

BJU Int. 2012 Jul;110(2):201-5. doi: 10.1111/j.1464-410X.2011.10709.x. Epub 2011 Nov 15.

17.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

18.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
19.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
20.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788

Supplemental Content

Support Center